Abstract
Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established two sublines of LNCaP prostate cancer (PC) cell line, one overexpressing AR 2–3-fold and the other 4–5-fold compared with the control cells. We used chromatin immunoprecipitation (ChIP) and deep-sequencing (seq) to identify AR-binding sites (ARBSs). We found that the number of ARBSs and the AR-binding strength were positively associated with the level of AR when cells were stimulated with low concentrations of androgens. In cells overexpressing AR, the chromatin binding of the receptor took place in 100-fold lower concentration of the ligand than in control cells. We confirmed the association of AR level and chromatin binding in two PC xenografts, one containing AR gene amplification with high AR expression, and the other with low expression. By combining the ChIP-seq and expression profiling, we identified AR target genes that are upregulated in PC. Of them, the expression of ZWINT, SKP2 (S-phase kinase-associated protein 2 (p45)) and FEN1 (flap structure-specific endonuclease 1) was demonstrated to be increased in CRPC, while the expression of SNAI2 was decreased in both PC and CRPC. FEN1 protein expression was also associated with poor prognosis in prostatectomy-treated patients. Finally, the knock-down of FEN1 with small interfering RNA inhibited the growth of LNCaP cells. Our data demonstrate that the overexpression of AR sensitizes the receptor binding to chromatin, thus, explaining how AR signaling pathway is reactivated in CRPC cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abramoff MD, Magelhaes PJ, Ram SJ . (2004). Image Processing with ImageJ. Biophotonics Int 11: 36–42.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192–1202.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39.
Cleutjens KBJM, van der Korput HAGM, van Eekelen CCEM, van Rooij HCJ, Faber PW, Trapman J . (1997). An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11: 148–161.
Huggins C, Hodges CV . (2002). Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 168: 9–12.
Isaacs JT . (1994). Role of androgens in prostatic cancer. Vitam Horm 49: 433–502.
Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A et al. (2008). Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3: e3645.
Kang Z, Jänne OA, Palvimo JJ . (2004). Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 11: 2633–2648.
Karvonen U, Kallio PJ, Jänne OA, Palvimo JJ . (1997). Interaction of androgen receptors with androgen response element in intact cells. J Biol Chem 272: 15973–15979.
Kasowski M, Grubert F, Heffelfinger C, Hariharan M, Asabere A, Waszak SM et al. (2010). Variation in transcription factor binding among humans. Science 328: 232–235.
Keller A, Backes C, Al-Awadhi M, Gerasch A, Küntzer J, Kohlbacher O et al. (2008). GeneTrailExpress: a web-based pipeline for the statistical evaluation of microarray experiments. BMC Bioinformatics 9: 552.
Kokontis JM, Hay N, Liao S . (1998). Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941–953.
Kops GJ, Kim Y, Weaver BA, Mao Y, McLeod I, Yates III JR et al. (2005). ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol 169: 49–60.
Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ et al. (2006). Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int 98: 445–451.
Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramäki OR et al. (2010). Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845–2851.
Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464: 374–379.
Lin YT, Chen Y, Wu G, Lee WH . (2006). Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 25: 6901–6914.
Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T . (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550–3555.
Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W et al. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132: 958–970.
Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871–878.
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30: 2719.
Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A et al. (2006). TRANSFAC(r) and its module TRANSCompel(r): transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: D108–D110.
Nakayama KI, Nakayama K . (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369–381.
Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH et al. (2011). The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol 29: 302–308.
Obuse C, Iwasaki O, Kiyomitsu T, Goshima G, Toyoda Y, Yanagida M . (2004). A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat Cell Biol 6: 1135–1141.
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC et al. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489–1495.
Roudier MP, Corey E, True LD, Higano CS, Ott SM, Vessella RL . (2004). Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. In: Keller E, Chung L (eds). The Biology of Skeletal Metastases vol. 118. Kluwer Academic Publishers: Boston, MA, USA, pp 311–339.
Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR . (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271: 7043–7051.
Seruga B, Ocana A, Tannock IF . (2011). Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 12–23.
Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C et al. (2010). The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120: 4478–4492.
Starr DA, Saffery R, Li Z, Simpson AE, Choo KH, Yen TJ et al. (2000). HZwint-1, a novel human kinetochore component that interacts with HZW10. J Cell Sci 113: 1939–1950.
Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K et al. (2010). Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30: 619–630.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11–22.
Thiery JP . (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 6: 442–454.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224.
Thompson J, Lepikhova T, Teixido-Travesa N, Whitehead MA, Palvimo JJ, Jänne OA . (2006). Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J 25: 2757–2767.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787–790.
Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T . (2008). Androgen regulation of the androgen receptor coregulators. BMC Cancer 8: 219.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406.
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA et al. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141–8149.
Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen P, Latonen L et al. (2011). Androgen regulation of microRNAs in prostate cancer. Prostate 71: 604–614.
Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F et al. (2001). Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15: 765–782.
Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y et al. (2011). Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474: 390–394.
Wang Q, Carroll JS, Brown M . (2005). Spatial and temporal recruitment of androgen receptor and its coactivatos involves chromosomal looping and polymerase tracking. Mol Cell 19: 631–642.
Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK et al. (2007). A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380–392.
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245–256.
Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M et al. (2010). Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147–2160.
Xu H, Zheng L, Dai H, Zhou M, Hua Y, Shen B . (2011). Chemical-induced cancer incidence and underlying mechanisms in Fen1 mutant mice. Oncogene 30: 1072–1081.
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443–445.
Zheng L, Dai H, Zhou M, Li M, Singh P, Qiu J et al. (2007). Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med 13: 812–819.
Zheng L, Jia J, David Finger L, Guo Z, Zer C, Shen B . (2010). Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res 39: 781–794.
Zinzen RP, Girardot C, Gagneur J, Braun M, Furlong EE . (2009). Combinatorial binding predicts spatio-temporal cis-regulatory activity. Nature 462: 65–70.
Acknowledgements
We wish to thank Ms Mariitta Vakkuri, Ms Päivi Martikainen and Mr Rolle Rahikainen for the skillful technical assistance. The research leading to these results has received funding from the European Union FP6, CANCURE Programme (contract number: MEST-CT-2005-020970). In addition, grant support has been received from Academy of Finland, Cancer Society of Finland, Reino Lahtikari Foundation, Sigrid Juselius Foundation, and the Medical Research Fund of Tampere University Hospital.
Author contributions: TV and AU designed the study, analyzed the data and wrote the paper. AU and BS performed experiments and edited the paper. JS, AL, HL performed the bioinformatic analyses and edited the paper. LML performed experiments and edited the paper. KKW provided the expression data and edited the paper. OAJ contributed new reagents and edited the paper. TLT provided clinical material and edited the paper. RLV provided the xenografts material and edited the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Urbanucci, A., Sahu, B., Seppälä, J. et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31, 2153–2163 (2012). https://doi.org/10.1038/onc.2011.401
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.401
Keywords
This article is cited by
-
Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells
Medical Oncology (2023)
-
The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer
Journal of Experimental & Clinical Cancer Research (2022)
-
Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
BMC Medical Genomics (2022)
-
The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression
Oncogene (2019)
-
An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia
Scientific Reports (2018)